Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an announcement.
Shandong Xinhua Pharmaceutical Company Limited announced that its subsidiary, Shandong Zibo Xincat Pharmaceutical Company Limited, has received a Drug Registration Certificate for its Finasteride tablets from the National Medical Products Administration. This approval marks a significant step for the company, potentially enhancing its market presence and offering new opportunities for growth in the pharmaceutical sector.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the production and distribution of prescription drugs. The company operates in the pharmaceutical industry and is involved in the development and manufacturing of various medicinal products.
Average Trading Volume: 9,824,744
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.69B
For an in-depth examination of 0719 stock, go to TipRanks’ Overview page.